Aug 4, 2026 · 2 min read
Otsuka's Kidney Drug Keeps Function Loss Near Normal Aging Rate for Two Full Years
Two-year Phase 3 data show sibeprenlimab slows IgA nephropathy patients' kidney decline to roughly the rate seen in healthy aging, a result Otsuka Holdings is using to push VOYXACT toward full US approval.